Pfizer pays $59.7 million over Biohaven kickbacks tied to migraine drug Nurtec
Pfizer agreed to pay $59,746,277 to resolve DOJ allegations that its subsidiary Biohaven, before the acquisition, paid kickbacks to health care providers to induce prescriptions of Nurtec ODT. The government alleged speaker honoraria and high-end meals violated the Anti-Kickback Statute between March 2020 and September 2022.
Pfizer Inc. agreed to pay $59,746,277 to resolve allegations that Biohaven Pharmaceutical Holding Company Ltd., which it acquired in 2022, violated the False Claims Act by paying kickbacks to induce prescriptions of the migraine drug Nurtec ODT, the Justice Department announced on January 24, 2025. The conduct at issue predates Pfizer's ownership. About $50.2 million of the settlement is the federal recovery, with about $9.5 million going to state Medicaid programmes.
The government alleged that between March 1, 2020 and September 30, 2022, Biohaven paid improper remuneration to health care professionals, including speaker honoraria and meals at high-end restaurants, in violation of the Anti-Kickback Statute, causing false claims to be submitted to Medicare and other federal health care programmes. Prosecutors alleged that some prescribers attended repeat programmes on the same topic with no educational benefit. The qui tam case was filed in 2021 by a former Biohaven sales representative, and the whistleblower will receive $8.4 million. Michigan Attorney General Dana Nessel said some providers were paid tens of thousands of dollars, in some cases more than $100,000.
Pfizer resolved the allegations without admitting wrongdoing. The government said the alleged conduct ended in October 2022, when Pfizer acquired Biohaven and terminated the Nurtec speaker programmes. US Attorney Trini E. Ross of the Western District of New York said patients should be able to trust that prescribing decisions reflect medical judgment rather than financial incentives.
Nurtec was the centrepiece of Pfizer's $11.6 billion purchase of Biohaven and generated $928 million in sales in 2023. The resolution shows that an acquiring company can carry False Claims Act liability for a target's marketing conduct before the deal closed, a point with direct relevance to pharmaceutical M&A due diligence.
The Biohaven matter is resolved. Pfizer separately faces a consumer protection lawsuit filed in June 2024 by Kansas Attorney General Kris Kobach alleging misrepresentations about its COVID-19 vaccine; a federal judge returned that case to Kansas state court in May 2025. The Texas Attorney General has filed a separate suit over Pfizer's COVID-19 vaccine claims.
Cite this report
The Precedent. "Pfizer pays $59.7 million over Biohaven kickbacks tied to migraine drug Nurtec." August 30, 2026. https://theprecedent.org/article/pfizer-pays-597-million-over-biohaven-kickbacks-tied-to-migraine-drug-nurtec
